NURS 6630 MIDTERM EXAM
Psychopharmacologic Approaches to Treatment of Psychopathology
Latest Version, 2026/2027 | 150 Questions & Answers | 100% Correct
Course: NURS 6630 - Psychopharmacologic Approaches to Treatment of Psychopathology | Institution: Walden
University | Exam Type: Midterm
Cognitive Distribution: 20% Recall | 50% Application | 30% Analysis | Question Style: 75% Scenario-Based |
25% Direct Knowledge
Aligned with: Walden University NURS 6630 Course Syllabus | AACN Essentials of Master's Education | PMHNP
Psychopharmacology Competencies (2026/2027 Edition)
Section 1: Principles of Psychopharmacology
Q1: A 42-year-old patient is started on fluoxetine 20 mg daily for major depressive disorder. The PMHNP
understands that fluoxetine is primarily metabolized by which cytochrome P450 enzyme, and that this has
significant implications for drug interactions?
A. CYP3A4
B. CYP2D6 *[CORRECT]*
C. CYP2C19
D. CYP1A2
Correct Answer: B
Rationale: Fluoxetine is a potent inhibitor of CYP2D6 and is itself metabolized by CYP2D6. This creates significant drug
interactions with medications metabolized by this enzyme, such as TCAs, beta-blockers, and antipsychotics. CYP3A4,
CYP2C19, and CYP1A2 are different isoenzymes with different substrate profiles. Understanding CYP450 enzymology is
foundational to the NURS 6630 curriculum and is essential for safe prescriptive practice.
Q2: A patient on lithium therapy presents with coarse tremor, confusion, and ataxia. The lithium level is 2.8
mEq/L. Which pharmacokinetic principle explains why lithium toxicity can develop rapidly in this patient who
recently started an NSAID for arthritis?
A. NSAIDs displace lithium from plasma protein binding sites
B. NSAIDs reduce renal lithium clearance by decreasing renal prostaglandin-mediated renal blood flow
*[CORRECT]*
C. NSAIDs enhance hepatic metabolism of lithium
D. NSAIDs increase gastrointestinal absorption of lithium
Correct Answer: B
Rationale: Lithium is excreted almost entirely by the kidneys and is not metabolized by the liver. NSAIDs reduce renal
prostaglandin production, which decreases renal blood flow and glomerular filtration rate, leading to sodium retention. Since
the kidney cannot distinguish lithium from sodium, reduced sodium excretion causes increased lithium reabsorption, raising
serum levels. The other options are incorrect: lithium is not protein-bound, is not hepatically metabolized, and its GI
absorption is not significantly affected by NSAIDs.
Walden University | NURS 6630 | 2026/2027 Edition Page 1
,NURS 6630 - Midterm Exam (2026/2027)
Q3: Which statement accurately describes the pharmacogenomic implications of CYP2D6 polymorphisms for a
PMHNP prescribing nortriptyline to a patient who is a CYP2D6 poor metabolizer?
A. The patient will require higher than standard doses to achieve therapeutic effect
B. The patient will have increased metabolism of nortriptyline, requiring dose reduction
C. The patient will have decreased metabolism of nortriptyline, requiring dose reduction and increased
monitoring for toxicity *[CORRECT]*
D. CYP2D6 polymorphisms do not affect nortriptyline metabolism
Correct Answer: C
Rationale: Nortriptyline is metabolized primarily by CYP2D6. Poor metabolizers have reduced enzyme activity, leading to
decreased drug clearance, higher plasma concentrations, and increased risk of anticholinergic and cardiac toxicity. These
patients require lower starting doses, slower titration, and more frequent therapeutic drug monitoring. Option A is incorrect
because poor metabolizers need less, not more, medication. Option B is wrong because it confuses poor metabolism with
ultra-rapid metabolism. Option D contradicts established pharmacogenomic evidence central to PMHNP competency.
Q4: A PMHNP is educating a patient on the importance of therapeutic drug monitoring (TDM) for a newly
prescribed medication. Which of the following medications most reliably requires TDM to guide dosing and
minimize toxicity?
A. Sertraline for major depressive disorder
B. Lithium for bipolar I disorder *[CORRECT]*
C. Quetiapine for schizophrenia
D. Mirtazapine for depression with insomnia
Correct Answer: B
Rationale: Lithium has a narrow therapeutic window (0.6-1.2 mEq/L for maintenance, with toxicity above 1.5 mEq/L),
requiring routine serum level monitoring. SSRIs like sertraline, atypical antipsychotics like quetiapine, and atypical
antidepressants like mirtazapine do not require routine TDM because their therapeutic ranges are less clearly defined and
clinical response guides dosing. The NURS 6630 curriculum emphasizes lithium TDM as a model for understanding
pharmacokinetic principles, including steady state, half-life (approximately 24 hours), and the need to draw levels 12 hours
after the last dose.
Q5: Which pharmacodynamic concept best explains why a patient taking clozapine requires weekly CBC
monitoring for the first 6 months of therapy?
A. Clozapine has high affinity for the D2 receptor causing extrapyramidal symptoms
B. Clozapine exhibits a dose-dependent idiosyncratic agranulocytosis affecting bone marrow precursor
cells *[CORRECT]*
C. Clozapine causes direct bone marrow suppression through 5-HT2A antagonism
D. Clozapine's anticholinergic effects lead to immune system suppression
Correct Answer: B
Rationale: Clozapine carries a black box warning for agranulocytosis, a potentially fatal idiosyncratic reaction occurring in
approximately 0.8% of patients. The mechanism involves dose-independent, immune-mediated destruction of neutrophil
precursors, not direct receptor-mediated suppression. While clozapine does have D2 antagonism, 5-HT2A antagonism, and
anticholinergic effects, none of these explain agranulocytosis. REMS-mandated weekly CBC monitoring for 6 months, then
every 2 weeks for 6 months, then monthly, is mandatory prescriptive authority knowledge for the PMHNP.
Walden University | NURS 6630 | 2026/2027 Edition Page 2
,NURS 6630 - Midterm Exam (2026/2027)
Q6: A patient taking paroxetine requests a refill after running out 4 days ago and reports dizziness, nausea, and
"electric shock" sensations in the head. The PMHNP recognizes this as discontinuation syndrome. Which
pharmacokinetic property of paroxetine most contributes to this phenomenon?
A. Long half-life allowing gradual washout
B. Short half-life of approximately 21 hours with no active metabolites *[CORRECT]*
C. High affinity for muscarinic receptors causing cholinergic rebound
D. Significant 5-HT2C antagonism
Correct Answer: B
Rationale: Paroxetine has a short half-life (approximately 21 hours) and lacks active metabolites, making it the SSRI most
associated with discontinuation syndrome. The abrupt reduction in serotonergic activity causes cholinergic and serotonergic
rebound. Fluoxetine, by contrast, has a long half-life (2-4 days) and an active metabolite (norfluoxetine, 7-15 days), naturally
tapering the patient and rarely causing discontinuation syndrome. Option C is incorrect because while paroxetine has
anticholinergic effects, the primary mechanism is serotonergic withdrawal, not cholinergic rebound.
Q7: A PMHNP prescriber is verifying state prescriptive authority for Schedule II controlled substances.
According to DEA regulations, which of the following statements is correct regarding a PMHNP with a DEA
registration number ending in the appropriate mid-level practitioner identifier?
A. Schedule II prescriptions can be called in for acute psychiatric emergencies with a 30-day supply
B. Schedule II prescriptions must be written (paper or electronic) and cannot be phoned in except in
genuine emergencies with follow-up written prescription within 7 days *[CORRECT]*
C. Schedule II medications can be refilled once with a single phone call to the pharmacy
D. Schedule II prescriptions expire 12 months from the date written
Correct Answer: B
Rationale: Under federal DEA regulations, Schedule II controlled substances require a written or electronic prescription.
Telephone orders are only permitted in genuine emergencies and must include a follow-up written prescription to the
pharmacy within 7 days. Schedule II medications cannot be refilled. Prescriptions generally expire according to state law
(often 6 months). The PMHNP must know both federal and state-specific prescriptive authority, controlled substance
schedules, and documentation requirements per the NURS 6630 curriculum.
Q8: A 68-year-old patient with hepatic impairment is started on a medication that is highly protein-bound and
hepatically metabolized. Which pharmacokinetic parameter is most directly affected by hepatic impairment in
this patient?
A. Volume of distribution of a water-soluble drug
B. Production of albumin affecting free drug fraction *[CORRECT]*
C. Renal clearance of the medication
D. Gastric pH affecting absorption
Correct Answer: B
Rationale: Hepatic impairment reduces the synthesis of albumin, the primary plasma protein to which many psychotropic
medications bind (e.g., fluoxetine, diazepam, valproate). Decreased albumin increases the free (active) fraction of the drug,
potentially causing toxicity even when total drug levels appear therapeutic. Water-soluble drugs have a larger volume of
distribution that is not directly affected by protein binding. Renal clearance and gastric pH are independent of hepatic
function. The PMHNP must integrate pharmacokinetic principles with patient-specific factors to individualize dosing.
Walden University | NURS 6630 | 2026/2027 Edition Page 3
, NURS 6630 - Midterm Exam (2026/2027)
Q9: When obtaining informed consent for psychotropic medication, which element is most consistent with the
AACN Essentials of Master's Education and PMHNP ethical practice standards?
A. Informing the patient that the medication will cure their condition
B. Documenting the patient's verbal agreement without discussing side effects to avoid frightening them
C. Discussing the indication, expected benefits, common and serious risks, alternatives, and the
consequences of refusing treatment, with documentation of understanding *[CORRECT]*
D. Telling the patient that the medication is standard of care so no alternatives exist
Correct Answer: C
Rationale: Informed consent requires disclosure of the indication, anticipated benefits, material risks (common and serious),
reasonable alternatives, and consequences of refusing treatment. Documentation must reflect the patient's understanding.
Options A and B are unethical and legally risky. Option D is false—alternatives almost always exist (e.g., psychotherapy,
different medications, no treatment). The NURS 6630 curriculum emphasizes patient education and ethical prescriptive
practice as PMHNP competencies per AACN Essentials.
Q10: The P-glycoprotein (P-gp) efflux transporter at the blood-brain barrier is inhibited by which medication,
leading to increased central nervous system concentrations of co-administered substrates like loperamide or
digoxin?
A. Phenytoin
B. Quinidine *[CORRECT]*
C. Carbamazepine
D. Rifampin
Correct Answer: B
Rationale: P-glycoprotein is an efflux transporter that pumps substrates out of the CNS back into the bloodstream. Quinidine
is a potent P-gp inhibitor, increasing CNS levels of substrates like loperamide (causing respiratory depression despite its
peripheral-only status otherwise) and digoxin. Phenytoin, carbamazepine, and rifampin are P-gp inducers, which decrease
substrate concentrations. The NURS 6630 curriculum addresses P-gp as part of advanced drug interaction mechanisms
beyond CYP450 metabolism.
Q11: A patient of African descent is prescribed clomipramine for OCD. The PMHNP considers
pharmacogenomic testing, knowing that this population has a higher prevalence of which CYP2D6 phenotype
that may affect drug metabolism?
A. Ultra-rapid metabolizer
B. Poor metabolizer *[CORRECT]*
C. Intermediate metabolizer
D. Extensive (normal) metabolizer
Correct Answer: B
Rationale: Approximately 5-10% of Caucasians and a smaller percentage of African-descent populations are CYP2D6 poor
metabolizers. However, gene duplications resulting in ultra-rapid metabolism are more common in individuals of North
African and Middle Eastern descent (up to 29% in some North African populations). This may lead to treatment failure with
pro-drugs or toxicity with active drugs. PMHNPs should consider pharmacogenomic testing when patients have unexpected
responses. The NURS 6630 curriculum emphasizes individualized pharmacotherapy through pharmacogenomics.
Walden University | NURS 6630 | 2026/2027 Edition Page 4
Psychopharmacologic Approaches to Treatment of Psychopathology
Latest Version, 2026/2027 | 150 Questions & Answers | 100% Correct
Course: NURS 6630 - Psychopharmacologic Approaches to Treatment of Psychopathology | Institution: Walden
University | Exam Type: Midterm
Cognitive Distribution: 20% Recall | 50% Application | 30% Analysis | Question Style: 75% Scenario-Based |
25% Direct Knowledge
Aligned with: Walden University NURS 6630 Course Syllabus | AACN Essentials of Master's Education | PMHNP
Psychopharmacology Competencies (2026/2027 Edition)
Section 1: Principles of Psychopharmacology
Q1: A 42-year-old patient is started on fluoxetine 20 mg daily for major depressive disorder. The PMHNP
understands that fluoxetine is primarily metabolized by which cytochrome P450 enzyme, and that this has
significant implications for drug interactions?
A. CYP3A4
B. CYP2D6 *[CORRECT]*
C. CYP2C19
D. CYP1A2
Correct Answer: B
Rationale: Fluoxetine is a potent inhibitor of CYP2D6 and is itself metabolized by CYP2D6. This creates significant drug
interactions with medications metabolized by this enzyme, such as TCAs, beta-blockers, and antipsychotics. CYP3A4,
CYP2C19, and CYP1A2 are different isoenzymes with different substrate profiles. Understanding CYP450 enzymology is
foundational to the NURS 6630 curriculum and is essential for safe prescriptive practice.
Q2: A patient on lithium therapy presents with coarse tremor, confusion, and ataxia. The lithium level is 2.8
mEq/L. Which pharmacokinetic principle explains why lithium toxicity can develop rapidly in this patient who
recently started an NSAID for arthritis?
A. NSAIDs displace lithium from plasma protein binding sites
B. NSAIDs reduce renal lithium clearance by decreasing renal prostaglandin-mediated renal blood flow
*[CORRECT]*
C. NSAIDs enhance hepatic metabolism of lithium
D. NSAIDs increase gastrointestinal absorption of lithium
Correct Answer: B
Rationale: Lithium is excreted almost entirely by the kidneys and is not metabolized by the liver. NSAIDs reduce renal
prostaglandin production, which decreases renal blood flow and glomerular filtration rate, leading to sodium retention. Since
the kidney cannot distinguish lithium from sodium, reduced sodium excretion causes increased lithium reabsorption, raising
serum levels. The other options are incorrect: lithium is not protein-bound, is not hepatically metabolized, and its GI
absorption is not significantly affected by NSAIDs.
Walden University | NURS 6630 | 2026/2027 Edition Page 1
,NURS 6630 - Midterm Exam (2026/2027)
Q3: Which statement accurately describes the pharmacogenomic implications of CYP2D6 polymorphisms for a
PMHNP prescribing nortriptyline to a patient who is a CYP2D6 poor metabolizer?
A. The patient will require higher than standard doses to achieve therapeutic effect
B. The patient will have increased metabolism of nortriptyline, requiring dose reduction
C. The patient will have decreased metabolism of nortriptyline, requiring dose reduction and increased
monitoring for toxicity *[CORRECT]*
D. CYP2D6 polymorphisms do not affect nortriptyline metabolism
Correct Answer: C
Rationale: Nortriptyline is metabolized primarily by CYP2D6. Poor metabolizers have reduced enzyme activity, leading to
decreased drug clearance, higher plasma concentrations, and increased risk of anticholinergic and cardiac toxicity. These
patients require lower starting doses, slower titration, and more frequent therapeutic drug monitoring. Option A is incorrect
because poor metabolizers need less, not more, medication. Option B is wrong because it confuses poor metabolism with
ultra-rapid metabolism. Option D contradicts established pharmacogenomic evidence central to PMHNP competency.
Q4: A PMHNP is educating a patient on the importance of therapeutic drug monitoring (TDM) for a newly
prescribed medication. Which of the following medications most reliably requires TDM to guide dosing and
minimize toxicity?
A. Sertraline for major depressive disorder
B. Lithium for bipolar I disorder *[CORRECT]*
C. Quetiapine for schizophrenia
D. Mirtazapine for depression with insomnia
Correct Answer: B
Rationale: Lithium has a narrow therapeutic window (0.6-1.2 mEq/L for maintenance, with toxicity above 1.5 mEq/L),
requiring routine serum level monitoring. SSRIs like sertraline, atypical antipsychotics like quetiapine, and atypical
antidepressants like mirtazapine do not require routine TDM because their therapeutic ranges are less clearly defined and
clinical response guides dosing. The NURS 6630 curriculum emphasizes lithium TDM as a model for understanding
pharmacokinetic principles, including steady state, half-life (approximately 24 hours), and the need to draw levels 12 hours
after the last dose.
Q5: Which pharmacodynamic concept best explains why a patient taking clozapine requires weekly CBC
monitoring for the first 6 months of therapy?
A. Clozapine has high affinity for the D2 receptor causing extrapyramidal symptoms
B. Clozapine exhibits a dose-dependent idiosyncratic agranulocytosis affecting bone marrow precursor
cells *[CORRECT]*
C. Clozapine causes direct bone marrow suppression through 5-HT2A antagonism
D. Clozapine's anticholinergic effects lead to immune system suppression
Correct Answer: B
Rationale: Clozapine carries a black box warning for agranulocytosis, a potentially fatal idiosyncratic reaction occurring in
approximately 0.8% of patients. The mechanism involves dose-independent, immune-mediated destruction of neutrophil
precursors, not direct receptor-mediated suppression. While clozapine does have D2 antagonism, 5-HT2A antagonism, and
anticholinergic effects, none of these explain agranulocytosis. REMS-mandated weekly CBC monitoring for 6 months, then
every 2 weeks for 6 months, then monthly, is mandatory prescriptive authority knowledge for the PMHNP.
Walden University | NURS 6630 | 2026/2027 Edition Page 2
,NURS 6630 - Midterm Exam (2026/2027)
Q6: A patient taking paroxetine requests a refill after running out 4 days ago and reports dizziness, nausea, and
"electric shock" sensations in the head. The PMHNP recognizes this as discontinuation syndrome. Which
pharmacokinetic property of paroxetine most contributes to this phenomenon?
A. Long half-life allowing gradual washout
B. Short half-life of approximately 21 hours with no active metabolites *[CORRECT]*
C. High affinity for muscarinic receptors causing cholinergic rebound
D. Significant 5-HT2C antagonism
Correct Answer: B
Rationale: Paroxetine has a short half-life (approximately 21 hours) and lacks active metabolites, making it the SSRI most
associated with discontinuation syndrome. The abrupt reduction in serotonergic activity causes cholinergic and serotonergic
rebound. Fluoxetine, by contrast, has a long half-life (2-4 days) and an active metabolite (norfluoxetine, 7-15 days), naturally
tapering the patient and rarely causing discontinuation syndrome. Option C is incorrect because while paroxetine has
anticholinergic effects, the primary mechanism is serotonergic withdrawal, not cholinergic rebound.
Q7: A PMHNP prescriber is verifying state prescriptive authority for Schedule II controlled substances.
According to DEA regulations, which of the following statements is correct regarding a PMHNP with a DEA
registration number ending in the appropriate mid-level practitioner identifier?
A. Schedule II prescriptions can be called in for acute psychiatric emergencies with a 30-day supply
B. Schedule II prescriptions must be written (paper or electronic) and cannot be phoned in except in
genuine emergencies with follow-up written prescription within 7 days *[CORRECT]*
C. Schedule II medications can be refilled once with a single phone call to the pharmacy
D. Schedule II prescriptions expire 12 months from the date written
Correct Answer: B
Rationale: Under federal DEA regulations, Schedule II controlled substances require a written or electronic prescription.
Telephone orders are only permitted in genuine emergencies and must include a follow-up written prescription to the
pharmacy within 7 days. Schedule II medications cannot be refilled. Prescriptions generally expire according to state law
(often 6 months). The PMHNP must know both federal and state-specific prescriptive authority, controlled substance
schedules, and documentation requirements per the NURS 6630 curriculum.
Q8: A 68-year-old patient with hepatic impairment is started on a medication that is highly protein-bound and
hepatically metabolized. Which pharmacokinetic parameter is most directly affected by hepatic impairment in
this patient?
A. Volume of distribution of a water-soluble drug
B. Production of albumin affecting free drug fraction *[CORRECT]*
C. Renal clearance of the medication
D. Gastric pH affecting absorption
Correct Answer: B
Rationale: Hepatic impairment reduces the synthesis of albumin, the primary plasma protein to which many psychotropic
medications bind (e.g., fluoxetine, diazepam, valproate). Decreased albumin increases the free (active) fraction of the drug,
potentially causing toxicity even when total drug levels appear therapeutic. Water-soluble drugs have a larger volume of
distribution that is not directly affected by protein binding. Renal clearance and gastric pH are independent of hepatic
function. The PMHNP must integrate pharmacokinetic principles with patient-specific factors to individualize dosing.
Walden University | NURS 6630 | 2026/2027 Edition Page 3
, NURS 6630 - Midterm Exam (2026/2027)
Q9: When obtaining informed consent for psychotropic medication, which element is most consistent with the
AACN Essentials of Master's Education and PMHNP ethical practice standards?
A. Informing the patient that the medication will cure their condition
B. Documenting the patient's verbal agreement without discussing side effects to avoid frightening them
C. Discussing the indication, expected benefits, common and serious risks, alternatives, and the
consequences of refusing treatment, with documentation of understanding *[CORRECT]*
D. Telling the patient that the medication is standard of care so no alternatives exist
Correct Answer: C
Rationale: Informed consent requires disclosure of the indication, anticipated benefits, material risks (common and serious),
reasonable alternatives, and consequences of refusing treatment. Documentation must reflect the patient's understanding.
Options A and B are unethical and legally risky. Option D is false—alternatives almost always exist (e.g., psychotherapy,
different medications, no treatment). The NURS 6630 curriculum emphasizes patient education and ethical prescriptive
practice as PMHNP competencies per AACN Essentials.
Q10: The P-glycoprotein (P-gp) efflux transporter at the blood-brain barrier is inhibited by which medication,
leading to increased central nervous system concentrations of co-administered substrates like loperamide or
digoxin?
A. Phenytoin
B. Quinidine *[CORRECT]*
C. Carbamazepine
D. Rifampin
Correct Answer: B
Rationale: P-glycoprotein is an efflux transporter that pumps substrates out of the CNS back into the bloodstream. Quinidine
is a potent P-gp inhibitor, increasing CNS levels of substrates like loperamide (causing respiratory depression despite its
peripheral-only status otherwise) and digoxin. Phenytoin, carbamazepine, and rifampin are P-gp inducers, which decrease
substrate concentrations. The NURS 6630 curriculum addresses P-gp as part of advanced drug interaction mechanisms
beyond CYP450 metabolism.
Q11: A patient of African descent is prescribed clomipramine for OCD. The PMHNP considers
pharmacogenomic testing, knowing that this population has a higher prevalence of which CYP2D6 phenotype
that may affect drug metabolism?
A. Ultra-rapid metabolizer
B. Poor metabolizer *[CORRECT]*
C. Intermediate metabolizer
D. Extensive (normal) metabolizer
Correct Answer: B
Rationale: Approximately 5-10% of Caucasians and a smaller percentage of African-descent populations are CYP2D6 poor
metabolizers. However, gene duplications resulting in ultra-rapid metabolism are more common in individuals of North
African and Middle Eastern descent (up to 29% in some North African populations). This may lead to treatment failure with
pro-drugs or toxicity with active drugs. PMHNPs should consider pharmacogenomic testing when patients have unexpected
responses. The NURS 6630 curriculum emphasizes individualized pharmacotherapy through pharmacogenomics.
Walden University | NURS 6630 | 2026/2027 Edition Page 4
